Drugs - Basaglar (insulin glargine) [Eli Lilly and Company]
June 2017
Therapeutic area - Insulin
90 mL per 34 days
Basaglar is approved by the FDA under the New Drug Application (NDA) pathway and is not considered an interchangeable biosimilar to Lantus. Basaglar is a long-acting human insulin analog, with an identical amino acid sequence to Lantus, indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
MHCP Provider Call Center 651-431-2700 or 800-366-5411